Showing results (741-750 of 1,838) with videos related to
Sort By:
Pageof 184
ESMO Open|March 6, 2025
Early CTLA4 increase in CD45+ blood cells: an emerging biomarker of atezolizumab-bevacizumab resistance and worse survival in advanced hepatocarcinomaL Gramantieri, A Montagner, A Arleo, et al.ESMO Open|March 15, 2025
The impact of co-occurring tumor suppressor mutations with mEGFR as early indicators of relapse in lung cancerS Hait, V Noronha, A Chowdhury, et al.ESMO Open|March 19, 2025
Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trialN Harbeck, V Dieras, K A Gelmon, et al.ESMO Open|October 12, 2024
Clinically meaningful outcomes in refractory metastatic colorectal cancer: a decade of defining and raising the barM Fakih, G W Prager, J Tabernero, et al.ESMO Open|October 10, 2024
Leptin as a surrogate immune-metabolic marker to predict impact of anti-cachectic therapy: results of a prospective randomized trial in multiple solid tumorsC Madeddu, G Gramignano, E Lai, et al.ESMO Open|October 16, 2024
Survival outcomes of young-age female patients with early breast cancer: an international multicenter cohort studyJ Kim, J Kim, K H Seo, et al.ESMO Open|August 9, 2024
Moderate physical activity during neoadjuvant chemotherapy in breast cancer patients: effect on cancer-related inflammation and pathological complete response-the Neo-Runner studyO Garrone, M Paccagnella, A Abbona, et al.ESMO Open|August 9, 2024
TRAbectedin in adVanced rEtroperitoneal well differentiated/dedifferentiated Liposarcoma and Leiomyosarcoma (TRAVELL): results of a phase II study from the Italian Sarcoma GroupC Fabbroni, G Grignani, B Vincenzi, et al.ESMO Open|August 23, 2024
HER2-low gastric cancer: is the subgroup targetable?K Shimozaki, S Fukuoka, A Ooki, et al.ESMO Open|September 4, 2024
Efficacy of chemotherapy after progression during or following PARPi exposure in ovarian cancerA Xu-Vuillard, C Guerin-Charbonnel, F Bocquet, et al.Pageof 184